Fifth Industry-Wide Trial Master File Reference Model Survey is Now Open
Make sure your perspective is heard, and get valuable insights and data for your TMF improvement initiatives
Make sure your perspective is heard, and get valuable insights and data for your TMF improvement initiatives. An outgrowth of the volunteer TMF Reference Model initiative, this survey is designed to provide year-over-year TMF details from sponsors, CROs, inspectors, and sites, for both paper and electronic TMF management. The intent is to identify TMF trends, assess changes in industry directions, and measure the impact of TMF models. Survey link: https://www.surveymonkey.com/s/TMF2015.
Survey completion takes ten minutes or less, depending on your organization. All respondents who complete the survey and provide contact details will be sent the results; no respondent is identified in the results.
The TMF Survey has been developed by volunteer members of the TMF Reference Model initiative. Information about us can be found at the end of the survey, and also at: http://tmfrefmodel.com.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
